---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-037749"
form_type: "8-K"
ticker: "FBIO"
cik: "0001429260"
company_name: "Fortress Biotech, Inc."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:08:12.436004+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Fortress Biotech reports 2025 results; ZYCUBO approved, PRV sold for $205M

## Summary
- ZYCUBO FDA-approved for Menkes disease; Cyprium sold PRV for $205M gross, with potential $128M in sales milestones.
- Checkpoint acquired by Sun Pharma; Fortress received ~$28M upfront, up to $4.8M CVR, and 2.5% royalty on UNLOXCYT.
- Consolidated net loss attributable to common stockholders improved to $(1.9)M ($(0.07)/share) vs $(55.9)M ($(2.69)/share) in 2024.
- Revenue rose to $63.3M in 2025 from $57.7M in 2024, driven by Journey Medical's Emrosi and dermatology portfolio.
- Prepaid Oaktree loan to $15.0M outstanding; cash at $79.4M as of year-end 2025.

## SEC filing metadata
- accession: 0001104659-26-037749
- form_type: 8-K
- ticker: FBIO
- cik: 0001429260
- company_name: Fortress Biotech, Inc.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1429260/000110465926037749/0001104659-26-037749-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1429260/000110465926037749/fbio-20260331x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-037749
- JSON: https://secwatch.observer/filing/0001104659-26-037749.json
- Plain text: https://secwatch.observer/filing/0001104659-26-037749.txt

## Key facts
- Earnings Releases
  Fortress Biotech, Inc. reported financial results for the year ended December 31, 2025.
  - Period: the year ended December 31, 2025
  - Result: reported results
  source text: On March 31, 2026, Fortress Biotech, Inc. issued a press release to provide a corporate update and to announce its financial results for the year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1429260/000110465926037749/0001104659-26-037749-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.